Source-linked dosage record
ZEPBOUND dose chart
The Eli Lilly prescribing record for ZEPBOUND (tirzepatide), organized into a scan-friendly schedule without detaching it from the source document.
- Ingredient
- tirzepatide
- Schedule format
- Label prose rendered as a table
- Label published
- May 06, 2026
- Mirrored
- 2026-08-29
Answer first
Dose schedule
The source publishes the sequence in prose. CareCanon displays that rule as 6 inspectable rows.
| Weeks | Dosage | Phase |
|---|---|---|
| 1 through 4 | 2.5 mg | Starting dosage |
| 5 through 8 | 5 mg | Dose escalation · label-named maintenance option |
| 9 through 12 | 7.5 mg | Dose escalation |
| 13 through 16 | 10 mg | Dose escalation · label-named maintenance option |
| 17 through 20 | 12.5 mg | Dose escalation |
| 21 and onward | 15 mg | Maintenance dosage |
The manufacturer does not publish a titration table for ZEPBOUND. The label states the escalation as a rule, quoted below, and the schedule above is that rule set out as a table. No dose has been added, and every dose shown appears in the label’s own “Dosage Forms and Strengths” section.
“The recommended starting dosage is 2.5 mg injected subcutaneously once weekly for 4 weeks. Increase the dosage in 2.5 mg increments after at least 4 weeks until recommended maintenance dosage is achieved.”
Section 3 inventory
Strengths and presentations
This inventory is kept separate from the schedule: a marketed strength is not automatically a starting dose, maintenance dose or recommendation.
Marketed strengths in this brand record
- 2.5 mg
- 5 mg
- 7.5 mg
- 10 mg
- 12.5 mg
- 15 mg
Dosage forms
Injection
Named packages
- Single-dose pen
- Single-dose vial
- Multi-dose vial · 4 doses
- KwikPen · 4 doses
Source excerpt · 3 DOSAGE FORMS AND STRENGTHS
Injection: Clear, colorless to slightly yellow solution in pre-filled single-dose pens, single-dose vials, multi-dose vials, or single-patient-use KwikPens, each available in the following strengths. The multi-dose vials and single-patient-use KwikPen each contain 4 doses: Single-dose Pen or Vial 2.5 mg/0.5 mL 5 mg/0.5 mL 7.5 mg/0.5 mL 10 mg/0.5 mL 12.5 mg/0.5 mL 15 mg/0.5 mL Multi-dose Vial (4 doses per vial) Dose per Injection Total Strength per Total Volume Strength per mL 2.5 mg/0.6 mL 10 mg/2.4 mL 4.17 mg/mL 5 mg/0.6 mL 20 mg/2.4 mL 8.33 mg/mL 7.5 mg/0.6 mL 30 mg/2.4 mL 12.5 mg/mL 10 mg/0.6 mL 40 mg/2.4 mL 16.7 mg/mL 12.5 mg/0.6 mL 50 mg/2.4 mL 20.8 mg/mL 15 mg/0.6 mL 60 mg/2.4 mL 25 mg/mL Single-Patient-Use KwikPen (4 doses per KwikPen) Dose per Injection Total Strength per Total Vol…
Inspect the complete section on DailyMed ↗Source excerpts
What the label says
These excerpts preserve the section names used by the source. Open DailyMed for the complete prescribing information.
2 DOSAGE AND ADMINISTRATION
Recommended Dose Escalation Schedule The recommended starting dosage is 2.5 mg injected subcutaneously once weekly for 4 weeks. Increase the dosage in 2.5 mg increments after at least 4 weeks until recommended maintenance dosage is achieved. ( 2.1 ) Consider treatment response and tolerability when selecting the maintenance dosage. ( 2.1 ) Recommended Maintenance and Maximum Dosage Weight Reduction and Long-Term Maintenance: 5 mg, 10 mg, or 15 mg injected subcutaneously once weekly. ( 2.2 ) Obstructive Sleep Apnea: 10 mg or 15 mg injected subcutaneously once weekly. ( 2.2 ) Maximum Recommended…
2.1 Recommended Dose Escalation Schedule
The recommended starting dosage of ZEPBOUND for all indications is 2.5 mg injected subcutaneously once weekly for 4 weeks. The 2.5 mg dosage is for treatment initiation and is not approved as a maintenance dosage. Follow the dosage escalation below for all indications to reduce the risk of gastrointestinal adverse reactions [see Warnings and Precautions ( 5.2 ) and Adverse Reactions ( 6.1 )] . After 4 weeks, increase the dosage to 5 mg injected subcutaneously once weekly. The dosage may be increased in 2.5 mg increments, after at least 4 weeks on the current dose [see Dosage and Administration…
2.2 Recommended Maintenance and Maximum Dosage
Recommended Maintenance Dosage Weight Reduction and Long-Term Maintenance The recommended maintenance dosage is 5 mg, 10 mg, or 15 mg, injected subcutaneously once weekly. OSA The recommended maintenance dosage is 10 mg or 15 mg injected subcutaneously once weekly. Maximum Recommended Dosage The maximum dosage of ZEPBOUND for all indications is 15 mg injected subcutaneously once weekly.
2.3 Recommendations Regarding Missed Dose
If a dose is missed, instruct patients to administer ZEPBOUND as soon as possible within 4 days (96 hours) after the missed dose. If more than 4 days have passed, skip the missed dose and administer the next dose on the regularly scheduled day. In each case, patients can then resume their regular once weekly dosing schedule. The day of weekly administration can be changed, if necessary, as long as the time between the two doses is at least 3 days (72 hours).
Document history
Recent label changes
Only changes named in the label’s own recent-major-changes block appear here.
| Section | Change | Revised |
|---|---|---|
| 2.4 | Dosage and Administration | 01/2026 |
| 5.2 | Warnings and Precautions Severe Gastrointestinal Adverse Reactions | 02/2026 |
| 5.10 | Never Share a ZEPBOUND KwikPen Between Patients | 01/2026 |
Before using this record
Three useful distinctions
Is this a personal dosing recommendation?
No. It is a reference rendering of prescribing information. A licensed prescriber and pharmacist determine what applies to an individual.
Did the manufacturer publish this exact table?
No. The label states the schedule in prose; CareCanon keeps the source sentence beside the table it renders.
How can I tell whether the source changed?
Use the publication and mirror dates above, inspect the recent-change rows, and open the linked DailyMed record for the current complete document.